The Unique Operational Challenge of Cell Therapy Development
Cell therapy companies occupy a uniquely demanding operational space within biotech. Unlike small molecule drug developers, cell therapy companies must simultaneously manage complex manufacturing logistics, individualized patient treatment coordination, stringent chain-of-custody documentation, clinical trial administration, and regulatory engagement — often with relatively small teams.
A 2024 report from the Alliance for Regenerative Medicine found that early-to-mid stage cell therapy companies averaged 34 full-time equivalents, yet routinely managed operational complexity comparable to organizations three times that size. Administrative overhead was identified as the primary bottleneck cited by 61 percent of surveyed executives.
Virtual assistants are becoming a standard tool for managing that complexity.
High-Value Administrative Functions for Cell Therapy VAs
Clinical trial coordination support. Cell therapy trials involve intricate coordination between manufacturing sites, clinical sites, and patients. VAs handle routine correspondence with investigative sites, track training completion, manage meeting scheduling for study team calls, and compile status reports — keeping the coordination layer moving without consuming clinical operations bandwidth.
Regulatory document organization. IND maintenance, CMC documentation, and safety reporting generate enormous volumes of paperwork. VAs manage document libraries, track submission deadlines, format correspondence for regulatory agencies, and maintain version control across document sets.
Manufacturing coordination. Chain-of-custody documentation and vendor communication around starting material logistics and batch release are administrative tasks that VAs with appropriate training can support. This is particularly valuable during manufacturing scale-up phases when coordination volume spikes.
Investor and board communications. Cell therapy companies often maintain active investor relations programs, particularly in the period around clinical milestones. VAs manage CRM updates, draft routine investor communications, format board materials, and coordinate virtual and in-person board meeting logistics.
KOL engagement management. Building and maintaining key opinion leader relationships is critical for cell therapy companies approaching commercialization. VAs manage KOL contact databases, coordinate advisory board meeting logistics, and track engagement history — supporting the medical affairs function at a fraction of the cost of additional headcount.
Patient advocacy coordination. Many cell therapy companies maintain active relationships with patient advocacy organizations. VAs support this function by managing correspondence, coordinating event participation, and tracking advocacy engagement.
The Business Case for Cell Therapy VAs
Cell therapy development is among the most capital-intensive pathways in biotech, with per-patient treatment costs and clinical trial expenses that can exceed $2 million in early phases. In this environment, operational efficiency is not discretionary — it is a funding runway question.
A 2025 analysis by the Milken Institute on cell and gene therapy company operations found that administrative automation and outsourcing — including VA programs — was associated with a 15 to 20 percent reduction in G&A spending as a percentage of total burn in Series B and C stage companies.
For a company burning $5 million per quarter, that represents $750,000 to $1 million in potential annual savings that can be redirected toward clinical advancement.
Practical Considerations
Cell therapy environments carry heightened confidentiality requirements, including IP sensitivity around proprietary manufacturing processes and patient identity protections. VAs working in this context must operate under robust NDAs, follow strict data handling protocols, and have clear boundaries around what systems they access.
Selecting a VA service provider that has experience placing assistants in clinical and biotech environments — and that provides compliance-oriented onboarding — is essential.
Implementation Approach
Cell therapy companies consistently recommend starting VA integration in one clearly bounded function — investor communications and scheduling are the most frequently cited starting points — and expanding from there as workflows are documented and performance is established.
Companies looking for experienced, vetted virtual assistants can explore options at Stealth Agents, a professional VA provider with experience across life sciences and complex regulated environments.
As cell therapy companies race to advance their pipelines with lean teams, virtual assistants are providing the operational infrastructure that allows scientific and clinical talent to do what they do best.
Sources
- Alliance for Regenerative Medicine, Cell Therapy Company Operations Survey, 2024
- Milken Institute, Cell and Gene Therapy Operations Analysis, 2025
- Virtual Assistant Industry Report, VirtualAssistantVA.com, 2026